Hancock Jaffe Laboratories Inc
0.0 %
-25.99 %
Yet to be announced
Company Overview
Hancock Jaffe Laboratories Inc is a medical device company focused on developing tissue-engineered implants for cardiovascular diseases. The company's lead product candidates include the VenoValve, designed to treat chronic venous insufficiency in the deep veins of the leg, and the CoreoGraft, a vascular graft intended for use in coronary artery bypass surgery.
The company is currently in the development and clinical trial phase and has not yet generated revenue from its products.
Revenue Sources
Since the company is pre-revenue and still in the research and development phase, with no commercial products on the market, this criterion is not applicable at this time. The company's planned revenue will come from medical devices, which is a halal source.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Based on the financial data for the last four quarters, the company shows zero interest income and zero interest expense. Additionally, since the company is pre-revenue and in R&D phase, the interest ratio checks are not applicable at this stage of the company's development.
Operational Ethics
Based on available information from SEC filings and company disclosures, there is no evidence of any significant associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.
Login to join the discussion